跳至主要内容
临床试验/NCT06317246
NCT06317246Unknown不适用

Subtypes and Prognostic Factors in Erdheim-Chester Disease

Meyer Children's Hospital IRCCS2 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2020年9月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
70
试验地点
2
主要终点
Clinical characteristics of patients with Erdheim-Chester Disease

研究概览

简要总结

Erdheim-Chester Disease (ECD) is a rare form of histiocytosis characterized by the proliferation of blood cells, known as histiocytes, which infiltrate various organs and tissues, often causing irreversible damage. The causes of the pathology are still unknown. Although the disease typically affects adult individuals, cases of pediatric-onset ECD have been described. However, there is a lack of detailed information on the phenotypic characteristics of these patients, and reliable data on response to specific therapies and long-term outcomes are missing. Three patients referred to our reference center for Histiocytosis present a concomitant BRAF-mutated neoplasm. Such an association could be due to the presence of mosaicisms for the BRAF V600E mutation. Mosaicism is a biological event defined as the presence of more than one genetically dissimilar cell population in the same organism and is an increasingly studied field, both in normal and pathological conditions. If proven in ECD as well, this mechanism could contribute to providing answers to the still open questions regarding the development of this disease.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
1 Year 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Prevalent and incident patients (adults and pediatric), with histologically confirmed diagnosis of Erdheim-Chester Disease according to the latest diagnostic recommendations;
  • Signing of informed consent for study participation.

排除标准

  • Patients for whom clinical and imaging data are not available and for whom it is not possible to retrieve histological samples."

研究组 & 干预措施

Investigation of BRAF mosaicism

Experimental

The study of BRAF mosaicism will be conducted on biopsy samples from patients with ECD and other neoplasms co-occurring with the BRAFV600E mutation. The samples will be labeled with anti-Pu.1-Alexa Fluor 647 antibody (which binds to macrophages), then DNA will be extracted using FACS method and amplified using MDA (Qiagen Repli-G Single-Cell kit). Quality control will be performed using Quant-it (ThermoScientific) and Agilent 4200 TapeStation. Eligible samples will undergo digital droplet PCR (ddPCR) and sequencing. ddPCR probes for wild-type and mutant alleles will be used. Sequencing will be performed using Illumina HiSeq 2500 system

干预措施: Investigation of BRAF mosaicism (Genetic)

结局指标

主要结局

Clinical characteristics of patients with Erdheim-Chester Disease

时间窗: 4 years

Evaluation of clinical characteristics in extreme subtypes of Erdheim-Chester Disease

Prognostic factors of patients with Erdheim-Chester Disease

时间窗: 4 years

Evaluation of prognostic factors in extreme subtypes of Erdheim-Chester Disease

次要结局

未报告次要终点

研究者

发起方
Meyer Children's Hospital IRCCS
申办方类型
Other
责任方
Principal Investigator
主要研究者

Augusto Vaglio

Associate Professor of Nephrology, Principal Investigator

Meyer Children's Hospital IRCCS

研究点 (2)

Loading locations...

相似试验